Foreign portfolio investors have injected ₹15,800 crore into Indian healthcare stocks between July and mid-September 2026, ending a 14-month sell-off. This capital shift marks a change in sentiment toward the sector, driven by steady earnings growth and hospital expansion. However, analysts warn that valuations in certain segments like CDMOs are becoming expensive, requiring investors to be more selective.
After a 14-month period of net selling, foreign portfolio investors (FPIs) have returned to the Indian healthcare sector with significant capital. Between July and mid-September 2026, foreign inflows totaled ₹15,800 crore. This follows a difficult period between April 2025 and June 2026, during which FPIs withdrew ₹40,160 crore from the sector.
The renewed interest has supported the performance of the Nifty Healthcare index, which is up 15 percent year-to-date. This shift is not just a return to defensive investing but is instead tied to fundamental business drivers. Key factors attracting global capital include the expansion of domestic pharmaceutical businesses, the resilience of US generic markets, and the scaling of hospital and diagnostic infrastructure in India.
Emerging Growth Areas
Institutional investors are focusing on specialized segments. Opportunities in Contract Development and Manufacturing Organizations (CDMO) and the growing demand for new treatments, including GLP-1 related segments, are gaining attention. Hospitals are also a point of interest, with firms like Narayana Hrudayalaya being monitored for their ability to increase capacity and expand network footprints.
Valuation Risks and Stock Selectivity
Despite the positive outlook, the sector is not without risks. Analysts suggest that the phase of easy gains, where the entire sector rose together, has likely ended. Some pockets of the market, particularly in the CDMO and CRAMS-related spaces, are now trading at high valuations. This has led to caution among research desks, which are tightening their criteria for stock picking.
Large players such as Sun Pharmaceutical Industries and Cipla continue to be preferred for their established market presence. Similarly, companies with specialty export profiles, such as Torrent Pharmaceuticals and Divi’s Laboratories, remain in focus for their export momentum. However, investors are advised to prioritize companies that can consistently deliver earnings growth over those that are simply benefiting from sector-wide sentiment.
What Investors Should Monitor
Moving forward, the ability of companies to manage high valuations while maintaining earnings quality will be critical. Investors may watch for company-specific earnings performance and execution updates regarding capital projects in hospital networks. With valuations elevated in specific segments, tracking whether companies can meet growth expectations amidst potential margin pressure will be a key monitorable.